Page 200 - 2020_02-Haematologica-web

J.S. Vermaat et al.
types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-511.
20. Schrader AMR, Jansen PM, Willemze R, Vermeer MH, Cleton-Jansen AM, Somers SF, et al. High prevalence of MYD88 and CD79B mutations in intravascular large B- cell lymphoma. Blood. 2018;131(18):2086- 2089.
21. Zhou XA, Louissaint A, Jr., Wenzel A, Yang J, Martinez-Escala ME, Moy AP, et al. Genomic analyses identify recurrent alter- ations in immune evasion genes in diffuse large B cell lymphoma, leg type. J Invest Dermatol. 2018;138(11):2365-2376.
22. Bonzheim I, Giese S, Deuter C, Susskind D, Zierhut M, Waizel M, et al. High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates. Blood. 2015;126(1):76-79.
23. Cani AK, Soliman M, Hovelson DH, Liu CJ, McDaniel AS, Haller MJ, et al. Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to tar- geted therapies. Mod Pathol. 2016; 29(7):685-697.
24. Raja H, Salomao DR, Viswanatha DS, Pulido JS. Prevalence of Myd88 L265p mutation in histologically proven, diffuse large B-cell vtreoretinal lymphoma. Retina. 2016;36(3):624-628.
25. Taniguchi K, Takata K, Chuang SS, Miyata- Takata T, Sato Y, Satou A, et al. Frequent MYD88 L265P and CD79B mutations in primary breast diffuse large B-cell lym- phoma. Am J Surg Pathol. 2016; 40(3):324- 334.
26. Kraan W, van Keimpema M, Horlings HM, Schilder-Tol EJ, Oud ME, Noorduyn LA, et al. High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia. 2014; 28(3):719-720.
27. Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127(7):869-881.
28. Kersten MJ, Kraan W, Doorduijn J, Bromberg J, Lam K, Kluin PM, et al. Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations. Blood Cancer J. 2014;12;4:e266.
29. Kraan W, Horlings HM, van Keimpema M, Schilder-Tol EJ, Oud ME, Scheepstra C, et al. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lym- phomas presenting at immune-privileged
sites. Blood Cancer J. 2013; 3:e139.
30. Lee JH, Jeong H, Choi JW, Oh H, Kim YS. Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lym- phoma: a meta-analysis. Scientific reports.
2017;7(1):1785.
31. Yu S, Luo H, Pan M, Palomino LA, Song X,
Wu P, et al. High frequency and prognostic value of MYD88 L265P mutation in diffuse large B-cell lymphoma with R-CHOP treat- ment. Oncology Lett. 2018;15(2):1707-1715.
32. Vermaat JS, Pals ST, Younes A, Dreyling M, Federico M, Aurer I, et al. Precision medi- cine in diffuse large B-cell lymphoma: hit- ting the target. Haematologica. 2015; 100(8):989-993.
33. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classifica- tion of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282.
34. van Eijk R, Stevens L, Morreau H, van Wezel T. Assessment of a fully automated high-throughput DNA extraction method from formalin-fixed, paraffin-embedded tissue for KRAS, and BRAF somatic muta- tion analysis. Exp Mol Pathol. 2013; 94(1):121-125.
35. Sibinga Mulder BG, Mieog JS, Handgraaf HJ, Farina Sarasqueta A, Vasen HF, Potjer TP, et al. Targeted next-generation sequenc- ing of FNA-derived DNA in pancreatic can- cer. J Clin Pathol. 2017;70(2):174-178.
36. Schemper M, Smith TL. A note on quanti- fying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343-346.
37. Kim HT. Cumulative incidence in compet- ing risks data and competing risks regres- sion analysis. Clin Cancer Res. 2007;15;13(2 Pt 1):559-565.
38. Houwelingen HC PH. Dynamic Prediction in Clinical Survival Analysis. Chapman & Hall., 2012.
39. Zheng M, Perry AM, Bierman P, Loberiza F, Jr., Nasr MR, Szwajcer D, et al. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lym- phoma. Neuropathology. 2017;37(6):509- 516.
40. Rovira J, Karube K, Valera A, Colomer D, Enjuanes A, Colomo L, et al. MYD88 L265P mutations, but no other variants, identify a subpopulation of DLBLC patients of acti- vated B-cell origin, extranodal involvement, and poor outcome. Clin Cancer Res. 2016;22(11):10.
41. Dubois S, Viailly PJ, Bohers E, Bertrand P, Ruminy P, Marchand V, et al. Biological and clinical relevance of associated genomic
alterations in MYD88 L265P and non- L265P-mutated diffuse large B-cell lym- phoma: analysis of 361 cases. Clin Cancer Res. 2017;23(9):2232-2244.
42. Intlekofer AM, Joffe E, Batlevi CL, Hilden P, He J, Seshan VE, et al. Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clini- cal assay. Blood Cancer J. 2018;12;8(6):60.
43. Karube K, Enjuanes A, Dlouhy I, Jares P, Martin-Garcia D, Nadeu F, et al. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant path- ways and potential therapeutic targets. Leukemia. 2018;32(3):675-684.
44. Xu PP, Zhong HJ, Huang YH, Gao XD, Zhao X, Shen Y, et al. B-cell function gene mutations in diffuse large B-cell lym- phoma: a retrospective cohort study. EBioMedicine. 2017;16:106-114.
45. YuX,LiW,DengQ,LiL,HsiED,Young KH, et al. MYD88 L265P Mutation in lym- phoid malignancies. Cancer Res. 2018; 78(10):2457-2462.
46. de Groen RAL, Schrader AMR, Kersten MJ, Pals ST, Vermaat JSP. MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implica- tions. Haematologica. 2019;104(12):2337- 2248.
47. Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, et al. Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7(9):1018-1029.
48. Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31(6):833-43 e5.
49. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in dif- fuse large B cell lymphoma. Nat Med 2015; 21(8):922-926.
50. Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, et al. Circulating tumor DNA measurements as early outcome pre- dictors in diffuse large B-cell lymphoma. J Clin Oncol. 2018; 36(28):2845-2853.
51. Rossi D, Diop F, Spaccarotella E, Monti S, Zanni M, Rasi S, et al. Diffuse large B-cell lymphoma genotyping on the liquid biop- sy. Blood. 2017;129(14):1947-1957.
52. Hiemcke-Jiwa LS, Minnema MC, Radersma-van Loon JH, Jiwa NM, de Boer M, Leguit RJ, et al. The use of droplet digi- tal PCR in liquid biopsies: a highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid. Hematol Oncol. 2018;36(2):429-35.
434
haematologica | 2020; 105(2)